Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up – What’s Next?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $17.40, but opened at $17.87. Pulse Biosciences shares last traded at $18.04, with a volume of 23,965 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research report on Tuesday.

Pulse Biosciences Stock Up 5.3 %

The company has a 50 day moving average of $17.97 and a 200-day moving average of $16.70.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the previous year, the company posted ($0.19) earnings per share.

Insider Buying and Selling at Pulse Biosciences

In other news, Director Robert W. Duggan bought 55,256 shares of the stock in a transaction dated Friday, December 13th. The stock was bought at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the purchase, the director now directly owns 42,328,717 shares in the company, valued at $727,207,358.06. This trade represents a 0.13 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at approximately $1,100,456.24. The trade was a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 71.50% of the company’s stock.

Institutional Trading of Pulse Biosciences

Hedge funds have recently modified their holdings of the business. Franklin Resources Inc. bought a new position in shares of Pulse Biosciences in the 3rd quarter worth about $378,000. Barclays PLC grew its holdings in Pulse Biosciences by 361.4% in the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after purchasing an additional 23,738 shares during the period. Geode Capital Management LLC increased its stake in shares of Pulse Biosciences by 7.8% during the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock valued at $8,020,000 after purchasing an additional 33,200 shares in the last quarter. State Street Corp lifted its holdings in shares of Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after purchasing an additional 69,696 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Pulse Biosciences in the 3rd quarter worth approximately $588,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.